Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|September 27, 2021
New OWEAR Program Highlights Emerging De Facto Standards in Open-source Algorithms
Advertisement
The Open Wearables Initiative (OWEAR) announced a new program designed to identify and support open-source algorithms that are being adopted rapidly and may become de facto industry standards.
This OWEAR program uses the number and quality of references to “crowdsource” the identification of potential de facto standards. Once a potential standard is identified, OWEAR will create and maintain a searchable catalog that displays key information about the studies in which the algorithm has been employed, including the therapeutic area, population(s) studied, and number of participants.
OWEAR plans to create a new catalog for each open-source algorithm used in a wearable sensor or other connected health technology that generates more than 25 published papers and meets other quality metrics. The reference-count criterion indicates that the algorithm has garnered significant industry adoption. Shimmer Research, Inc. has agreed to donate the staff time to create and maintain these OWEAR catalogs.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
5